Preclinical data showed up to 97% inhibition of E. coli in a UTI model and in vivo activity in pulmonary infection models. Lead candidate Nu-3 Phase 2a iDFU data expected Q1 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
